13F Holdings
中文EN

VNDA Vanda Pharmaceuticals Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1347178 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY8.1%
TTM net income YoY-226.4%
TTM EPS YoY-220.8%
Revenue 3-yr CAGR2.7%
Net income 3-yr CAGR—

Margins

Gross margin93.6%
Operating margin-77.6%
Net margin-119.9%
FCF margin-61.0%
EBITDA margin-77.1%

Returns

ROE-82.5%
ROA-55.9%
ROIC (approx.)-52.6%
Asset turnover0.47x

Leverage & solvency

Liabilities / assets47.7%
Debt / equity0.00x
Current ratio1.54x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.51x
Accruals ratio-27.6%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$216.10M$198.77M$192.64M$254.38M$268.68M
Cost of revenue$13.04M$11.31M$14.80M$24.28M$25.63M
Gross profit$203.06M$187.46M$177.84M$230.10M$243.05M
R&D expense$109.27M$74.43M$76.82M$85.77M$75.36M
SG&A expense$237.95M$146.41M$112.88M$136.49M$124.05M
Operating income-$151.17M-$40.66M-$13.95M$6.33M$42.16M
Pretax income-$138.65M-$22.92M$6.34M$11.30M$42.36M
Income tax$81.83M-$4.02M$3.83M$5.03M$9.21M
Net income-$220.47M-$18.90M$2.51M$6.28M$33.15M
EBITDA-$150.06M-$39.80M-$13.03M$7.55M$43.53M
EPS (basic)-3.74-0.330.040.110.60
EPS (diluted)-3.74-0.330.040.110.58
Weighted avg. shares (diluted)58.93M58.15M57.56M56.98M56.92M
Balance sheet
Cash & equivalents$84.85M$102.78M$136.29M$135.50M$52.59M
Short-term investments————$380.74M
Receivables$54.58M$47.10M$34.16M$33.51M$32.47M
Inventory$1.85M$1.73M$1.36M$1.19M$1.02M
Current assets$347.26M$438.89M$432.95M$519.29M$478.30M
PP&E, net$2.25M$2.13M$2.04M$2.57M$3.11M
Intangibles$117.09M$114.10M$121.37M$18.57M$20.08M
Total assets$488.95M$656.20M$648.44M$634.25M$593.79M
Current liabilities$145.16M$99.98M$87.70M$91.44M$74.42M
Total liabilities$161.76M$117.66M$103.53M$107.05M$88.86M
Shareholders' equity$327.19M$538.55M$544.91M$527.20M$504.93M
Shares outstanding59.10M58.31M57.53M56.78M55.90M
Cash flow statement
Operating cash flow-$109.44M-$15.76M$12.80M$31.98M$64.21M
Capital expenditure$998,000$490,000$383,000$679,000$552,000
Free cash flow-$110.44M-$16.25M$12.42M$31.30M$63.66M
Investing cash flow$94.86M-$17.43M-$12.06M$49.92M-$76.70M
Financing cash flow-$2.91M-$155,000$0$734,000$3.55M
Depreciation & amortization$1.10M$859,000$920,000$1.22M$1.36M
Stock-based compensation$9.47M$12.43M$14.04M$16.28M$15.37M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.